

10.1302/2046-3758.1310.BJR-2024-0119.R1

Table i. Demographic characteristics.

Variable	Value
Male:female, n	9:27
Mean age, yrs (SD)	64.8 (13.6)
Mean BMI, kg/m ² (SD)	24.6 (5.1)
Hip:knee, n	22:15
Sinus tract, n (%)	15 (41.7)
Acute infection, n (%)	13 (36.1)
Chronic infection, n (%)	23 (63.9)
Mean preoperative ESR, mm/h (SD)	42 (39.3)
Mean preoperative CRP, mg/l (SD)	50 (22.1)
Mean preoperative IL-6, pg/ml (SD)	19.6 (10.2)
ASA grade, n (%)	
I	1 (2.8)
II	17 (47.2)
III	17 (47.2)
IV	1 (2.8)
MSIS category, n (%)	
A	18 (50)
B	16 (44.4)
C	2 (5.6)

ASA, American Society of Anesthesiologists; IL, interleukin; MSIS, Musculoskeletal Infection Society.

Table ii. Proportions of positive cultures by specimen type and treatment group.

Group	No. of positive cultures/total no. of specimens (%)			
	Soft-tissue	Bone	Prosthesis	Blood
Control	8/8 (100)	8/8 (100)	8/8 (100)	0/8 (0)
IP	4/8 (50)	5/8 (63)	6/8 (75)	0/8 (0)
IA	0/8 (0)	0/8 (0)	0/8 (0)	0/8 (0)
IP+IA	0/8 (0)	0/8 (0)	0/8 (0)	0/8 (0)

IA, intra-articular; IP, intraperitoneal.




Fig. a. Treatment regimens in rat study. *E. coli*, *Escherichia coli*.




Fig. b. Susceptibility of planktonic and biofilm *Escherichia coli* (*E. coli*) ATCC25922 to four antibiotics. a) Minimum inhibitory concentration (MIC) and b) minimum bactericidal concentration (MBC) for planktonic *E. coli*. c) Minimum biofilm inhibitory concentration (MBIC) and minimum biofilm eradication concentration (MBEC) for biofilm *E. coli*.




Fig. c. Mean and total doses of meropenem in the first or second seven days after one-stage revision. IA, intra-articular; IP, intraperitoneal. ** $p < 0.01$. One-way analysis of variance with Tukey's multiple comparison test or Kruskal-Wallis test with Dunn's multiple comparison test.